Emily Petersen, MD
Nephrology · Coeur D Alene, IDNPI 1750414447
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $335 of the $395 with a category attached, or 84.9%. Abbott accounts for 79.1% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $289 and has fallen 79.4% since, to $60 in 2024.
Across 23 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$312
- Travere Therapeutics, Inc.$60
- Otsuka America Pharmaceutical, Inc.$23
What the payments were for
- Food & beverage$33585%
- Education$6015%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 6 | $312 |
| Travere Therapeutics, Inc. | 16 | $60 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$395 in reported general payments places this provider in the 55th percentile of 30 nephrology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 146 | $175,805 |
| FarxigaDapagliflozin Propanediol | 51 | $45,920 |
| EntrestoSacubitril/Valsartan | 30 | $34,900 |
| Lanthanum Carbonate | 12 | $30,213 |
| KerendiaFinerenone | 15 | $27,407 |
| VeltassaPatiromer Calcium Sorbitex | 25 | $24,890 |
| Cinacalcet Hcl | 19 | $13,602 |
| TradjentaLinagliptin | 12 | $6,342 |
| XareltoRivaroxaban | 12 | $6,218 |
| Sevelamer Carbonate | 19 | $3,372 |
| Torsemide | 149 | $3,010 |
| Losartan Potassium | 256 | $2,394 |
| Clonidine | 11 | $2,160 |
| Potassium Citrate ErPotassium Citrate | 29 | $1,835 |
| Amlodipine Besylate | 242 | $1,703 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Coeur D Alene
- Tiana Jespersen NizamicCoeur D Alene$215
- Casey CotantCoeur D Alene$131
- Scott BieberCoeur D Alene$54
- Brendan MielkeCoeur D Alene$17
- Arnold SilvaMeridian$626K
- Liang WuMeridian$386K
- Mary DittrichMeridian$7K
- Shaun JoshiHayden$5K
- Heidi JoistNampa$4K
- Naeem RahimChubbuck$696
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.